Advanced search
Publication Cover
Drug Delivery Volume 27, 2020 - Issue 1
Submit an article Journal homepage
1,777
Views
17
CrossRef citations to date
0
Altmetric
Research Article

Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma

Renna Qiua Department of Physical Examination Center, China-Japan Union Hospital of Jilin University, Changchun, China; View further author information
,
Denghua Sunb Department of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun, China; View further author information
,
Yuzhuo Baic Breast and Thyroid Surgery, Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, China; View further author information
,
Jiannan Lid Department of General Surgery, The Second Hospital of Jilin University, Changchun, China; View further author information
&
Lizhe Wange Department of Pediatric Oncology, The First Hospital of Jilin University, Changchun, ChinaCorrespondence[email protected]
View further author information
Pages 1704-1717 | Received 28 Sep 2020, Accepted 23 Nov 2020, Published online: 11 Dec 2020

References

  • Botter SM, Neri D, Fuchs B. (2014). Recent advances in osteosarcoma. Curr Opin Pharmacol 16:15–23.
  • Chen L, Zhao L, Hu G, et al. (2020). Tumor-specific nanomedicine via sequential catalytic reactions for accurate tumor therapy. J Mater Chem B 8:6857–65.
  • Choi HS, Liu W, Misra P, et al. (2007). Renal clearance of quantum dots. Nat Biotechnol 25:1165–70.
  • Eaton BR, Schwarz R, Vatner R, et al. (2020). Osteosarcoma. Pediatr Blood Cancer e28352.
  • Feng X, Li J, Zhang X, et al. (2019). Electrospun polymer micro/nanofibers as pharmaceutical repositories for healthcare. J Control Release 302:19–41.
  • Gu X, Ding J, Zhang Z, et al. (2015). Polymeric nanocarriers for drug delivery in osteosarcoma treatment. Curr Pharm Des 21:5187–97.
  • Harrison DJ, Geller DS, Gill JD, et al. (2018). Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther 18:39–50.
  • Hayashi K, Zhao M, Yamauchi K, et al. (2009). Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain of Salmonella typhimurium. Cell Cycle 8:870–5.
  • Kolate A, Baradia D, Patil S, et al. (2014). PEG – a versatile conjugating ligand for drugs and drug delivery systems. J Control Release 192:67–81.
  • Li J, Xu W, Chen J, et al. (2018a). Highly bioadhesive polymer membrane continuously releases cytostatic and anti-inflammatory drugs for peritoneal adhesion prevention. ACS Biomater Sci Eng 4:2026–36.
  • Li J, Xu W, Li D, et al. (2018b). Locally deployable nanofiber patch for sequential drug delivery in treatment of primary and advanced orthotopic hepatomas. ACS Nano 12:6685–99.
  • Li S, Zhang T, Xu W, et al. (2018c). Sarcoma-targeting peptide-decorated polypeptide nanogel intracellularly delivers shikonin for upregulated osteosarcoma necroptosis and diminished pulmonary metastasis. Theranostics 8:1361–75.
  • Ma L, Xu Y, Xu X. (2020). Targeted MEK inhibition by cobimetinib enhances doxorubicin's efficacy in osteosarcoma models. Biochem Biophys Res Commun 529:622–8.
  • Maeda H, Nakamura H, Fang J. (2013). The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 65:71–9.
  • Marina N, Gebhardt M, Teot L, Gorlick R. (2004). Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9:422–41.
  • Qiu S, Tao L, Zhu Y. (2019). Marital status and survival in osteosarcoma patients: an analysis of the surveillance, epidemiology, and end results (SEER) database. Med Sci Monit 25:8190–203.
  • Ren X, Su C. (2020). Sphingosine kinase 1 contributes to doxorubicin resistance and glycolysis in osteosarcoma. Mol Med Rep 22:2183–90.
  • Schafer FQ, Buettner GR. (2001). Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 30:1191–212.
  • Strouhalova K, Přechová M, Gandalovičová A, et al. (2020). Vimentin intermediate filaments as potential target for cancer treatment. Cancers 12:184.
  • Su T, Yang B, Gao T, et al. (2020). Polymer nanoparticle-assisted chemotherapy of pancreatic cancer. Ther Adv Med Oncol 12:1758835920915978.
  • Torchilin V. (2011). Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 63:131–5.
  • Torchilin VP. (2007). Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J 9:E128–E47.
  • Wakhloo NT, Anders S, Badique F, et al. (2020). Actomyosin, vimentin and LINC complex pull on osteosarcoma nuclei to deform on micropillar topography. Biomaterials 234:119746.
  • Wang J, Byrne JD, Napier ME, Desimone JM. (2011). More effective nanomedicines through particle design. Small 7:1919–31.
  • Wang X, Ding X, Yu B, et al. (2020a). Tumor microenvironment-responsive polymer with chlorin e6 to interface hollow mesoporous silica nanoparticles-loaded oxygen supply factor for boosted photodynamic therapy. Nanotechnology 31:305709.
  • Wang X, Yang L, Fang Q, et al. (2020b). GLUT1-targeting and GSH-responsive DOX/L61 nanodrug particles for enhancing MDR breast cancer therapy. Part Part Syst Charact 37:2000165.
  • Yang B, Chen Y, Shi J. (2020). Tumor-specific chemotherapy by nanomedicine-enabled differential stress sensitization. Angew Chem Int Ed Engl 59:9693–701.
  • Yu Z, Xiao Z, Shuai X, Tian J. (2020). Local delivery of sunitinib and Ce6 via redox-responsive zwitterionic hydrogels effectively prevents osteosarcoma recurrence. J Mater Chem B 8:6418–28.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.